[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Silo Pharma Inc (SILO)

Silo Pharma Inc (SILO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Silo Pharma Secures $2.5M in Stock Sale Agreement

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Silo Pharma...

SILO : 0.3720 (-4.05%)
After a Patent Win, Analysts Think This Penny Stock Can Gain 465% in 2025

Amid the dynamic biopharma landscape, this penny stock is turning heads with a game-changing patent win, and analysts are buzzing with bullish projections for its potential.

SILO : 0.3720 (-4.05%)
Silo Pharma Announces Key Preclinical Study for SP-26, a Novel Non-Opioid Pain Therapeutic

Silo Pharma initiates a pharmacokinetic study for SP-26, a non-opioid treatment for chronic pain and fibromyalgia.Quiver AI SummarySilo Pharma, Inc. has announced the start of a pharmacokinetic and tolerability...

SILO : 0.3720 (-4.05%)
Silo Pharma Collaborates with Kymanox for Development of Subcutaneous Insertion Device for SP-26 Ketamine Implant

Silo Pharma collaborates with Kymanox to develop a subcutaneous device for its ketamine implant targeting chronic pain.Quiver AI SummarySilo Pharma, Inc. has announced a collaboration with Kymanox to develop...

SILO : 0.3720 (-4.05%)
Silo Pharma, Inc. Announces Promising Preclinical Results for Dual-action Treatment SPC-15 Targeting PTSD and Severe Stress-related Conditions

Silo Pharma's SPC-15 shows promising dual-target efficacy in preclinical studies for treating severe stress-related psychiatric conditions.Quiver AI SummarySilo Pharma, Inc. announced promising results...

SILO : 0.3720 (-4.05%)
Global Alzheimer’s Disease Diagnostics & Therapeutics Market Expected to Reach $9.6 Billion by 2027

Palm Beach, FL – May 9, 2023 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is a progressive and neurodegenerative disorder that attacks the brain’s nerve cells or neurons,...

TRVN : 0.0111 (unch)
IMRN : 0.9900 (-1.00%)
IMC.AX : 0.029 (-12.12%)
LLY : 1,019.02 (+3.13%)
ACOR : 0.6610 (-24.86%)
SILO : 0.3720 (-4.05%)
Global Alzheimer's Disease Diagnostics & Therapeutics Market Expected to Reach $9.6 Billion by 2027

/PRNewswire/ -- Alzheimer's disease (AD) is a progressive and neurodegenerative disorder that attacks the brain's nerve cells or neurons, which results in loss...

TRVN : 0.0111 (unch)
IMRN : 0.9900 (-1.00%)
LLY : 1,019.02 (+3.13%)
ACOR : 0.6610 (-24.86%)
SILO : 0.3720 (-4.05%)
Silo Pharma’s SPC-15 Awarded U.S. Patent to Protect Ongoing R&D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer’s Disease

ENGLEWOOD CLIFFS, NJ – May 9,  2023 – Silo Pharma, Inc.  (NASDAQ: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic...

SILO : 0.3720 (-4.05%)
Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety and PTSD Stress-Related Disorders

ENGLEWOOD CLIFFS, NJ – April 19, 2023 – Silo Pharma, Inc.  (NASDAQ:SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic...

SILO : 0.3720 (-4.05%)
Silo Pharma (NASDAQ: SILO) Provides Update on Study of Ketamine Formulations for Fibromyalgia

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused around merging traditional therapeutics with psychedelic research, recently announced that it had achieved a positive...

SILO : 0.3720 (-4.05%)
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.